Pharmacogenomics in the treatment of lung cancer: an update.

about

Immunotherapy meets targeted therapy: will this team end the war against cancer?On the pharmacogenetics of non-small cell lung cancer treatment.miR-215 suppresses proliferation and migration of non-small cell lung cancer cells

P2860

Q26769721-B2C4CCEE-A82D-4E47-A29A-728D25649D81 Q38694947-AA61B94D-CD38-4E70-A4E0-51EB93CDCB19 Q38705622-D2B7A7DF-7DD4-4282-BA96-AD225D5E45A7

P2860

Pharmacogenomics in the treatment of lung cancer: an update.

Item

http://www.wikidata.org/entity/Q38596926

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Pharmacogenomics in the treatment of lung cancer: an update.

@en

type

Item

label

Pharmacogenomics in the treatment of lung cancer: an update.

@en

prefLabel

Pharmacogenomics in the treatment of lung cancer: an update.

@en

P1476

Pharmacogenomics in the treatment of lung cancer: an update.

@en

P2093

Daniela Morales-Espinosa

http://www.w3.org/2001/XMLSchema#string

Niki Karachaliou

http://www.w3.org/2001/XMLSchema#string

Silvia García-Román

http://www.w3.org/2001/XMLSchema#string

P2860

The pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Identification of targetable FGFR gene fusions in diverse cancers.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

P304

1751-1760

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS.15.99

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rafael Rosell

P577

2015-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26427522

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

Pharmacogenomics in the treatment of lung cancer: an update.

about

P2860

P2860

Pharmacogenomics in the treatment of lung cancer: an update.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921